Valsartan recall

The Valsartan recall involved some batches of a medication used to treat high blood pressure and heart failure. The recall occurred because certain Valsartan medicines were found to contain traces of an impurity called N-nitrosodimethylamine (NDMA), which is a potential carcinogen. This impurity likely originated from changes in manufacturing processes. While the level of NDMA found was below what is considered safe, ongoing concerns prompted recalls to prevent any potential health risks. Patients taking Valsartan should consult their healthcare providers for guidance, but most who continued use at prescribed doses remained at minimal risk.